Proto-Oncogene Proteins c-raf

"Proto-Oncogene Proteins c-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A ubiquitously expressed raf kinase subclass that plays an important role in SIGNAL TRANSDUCTION. The c-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.

Descriptor ID	D019908
MeSH Number(s)	D08.811.913.696.620.682.700.559.842.500 D12.644.360.400.842.500 D12.776.476.400.842.500 D12.776.624.664.700.204.500
Concept/Terms	Proto-Oncogene Proteins c-raf Proto-Oncogene Proteins c-raf Proteins c-raf, Proto-Oncogene Proto Oncogene Proteins c raf c-raf, Proto-Oncogene Proteins Proto-Oncogene Protein c-raf Protein c-raf, Proto-Oncogene Proto Oncogene Protein c raf c-raf, Proto-Oncogene Protein c-raf Kinases Kinases, c-raf c raf Kinases Kinase Raf-1 Kinase Raf 1 Raf-1, Kinase cRaf1 Kinase Kinase, cRaf1 raf-1 Kinase Kinase, raf-1 raf 1 Kinase c-raf Proteins Proteins, c-raf c raf Proteins Kinase p74(raf-1)

Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-raf".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Serine-Threonine Kinases [D08.811.913.696.620.682.700]
MAP Kinase Kinase Kinases [D08.811.913.696.620.682.700.559]
raf Kinases [D08.811.913.696.620.682.700.559.842]
Proto-Oncogene Proteins c-raf [D08.811.913.696.620.682.700.559.842.500]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intracellular Signaling Peptides and Proteins [D12.644.360]
MAP Kinase Kinase Kinases [D12.644.360.400]
raf Kinases [D12.644.360.400.842]
Proto-Oncogene Proteins c-raf [D12.644.360.400.842.500]
Proteins [D12.776]
Intracellular Signaling Peptides and Proteins [D12.776.476]
MAP Kinase Kinase Kinases [D12.776.476.400]
raf Kinases [D12.776.476.400.842]
Proto-Oncogene Proteins c-raf [D12.776.476.400.842.500]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
raf Kinases [D12.776.624.664.700.204]
Proto-Oncogene Proteins c-raf [D12.776.624.664.700.204.500]

Below are MeSH descriptors whose meaning is related to "Proto-Oncogene Proteins c-raf".

Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-raf".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Proto-Oncogene Proteins c-raf" by people in this website by year, and whether "Proto-Oncogene Proteins c-raf" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2003 and 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
2001	1	0	1
2002	1	0	1
2003	1	1	2
2004	1	0	1
2009	2	0	2
2011	0	1	1

Below are the most recent publications written about "Proto-Oncogene Proteins c-raf" by people in Profiles.

Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, Force T. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res. 2011 Dec 09; 109(12):1401-9.

View in: PubMed
Smith J, Bunaciu RP, Reiterer G, Coder D, George T, Asaly M, Yen A. Retinoic acid induces nuclear accumulation of Raf1 during differentiation of HL-60 cells. Exp Cell Res. 2009 Aug 01; 315(13):2241-8.

View in: PubMed
Pinchot SN, Adler JT, Luo Y, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H. Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg. 2009 Mar; 197(3):313-9.

View in: PubMed
Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, Lessin SR, Weber BL. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet. 2004 Apr; 41(4):270-2.

View in: PubMed
Summy JM, Qian Y, Jiang BH, Guappone-Koay A, Gatesman A, Shi X, Flynn DC. The SH4-Unique-SH3-SH2 domains dictate specificity in signaling that differentiate c-Yes from c-Src. J Cell Sci. 2003 Jun 15; 116(Pt 12):2585-98.

View in: PubMed
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003 Feb 15; 63(4):756-9.

View in: PubMed
Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 01; 62(23):6997-7000.

View in: PubMed
Broustas CG, Grammatikakis N, Eto M, Dent P, Brautigan DL, Kasid U. Phosphorylation of the myosin-binding subunit of myosin phosphatase by Raf-1 and inhibition of phosphatase activity. J Biol Chem. 2002 Jan 25; 277(4):3053-9.

View in: PubMed
Xin X, Yang N, Eckhart AD, Faber JE. Alpha1D-adrenergic receptors and mitogen-activated protein kinase mediate increased protein synthesis by arterial smooth muscle. Mol Pharmacol. 1997 May; 51(5):764-75.

View in: PubMed
Prendergast GC, Gibbs JB. Ras regulatory interactions: novel targets for anti-cancer intervention? Bioessays. 1994 Mar; 16(3):187-91.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement